样式: 排序: IF: - GO 导出 标记为已读
-
Metabolism, toxicity and management of fruquintinib: a novel drug for metastatic colorectal cancer Expert Opin. Drug Metab. Toxicol. (IF 4.3) Pub Date : 2024-03-18 Kanchi Patell, Veronica Lee Mears, Michael H. Storandt, Amit Mahipal
Colorectal cancer (CRC) is the third most diagnosed cancer globally and despite therapeutic strides, the prognosis for patients with metastatic disease (mCRC) remains poor. Fruquintinib is an oral ...
-
A comprehensive update on the ADMET considerations for α2δ calcium channel ligand medications for treating restless legs syndrome Expert Opin. Drug Metab. Toxicol. (IF 4.3) Pub Date : 2024-03-15 Gaia Pellitteri, Salvatore Versace, Giovanni Merlino, Annacarmen Nilo, Gian Luigi Gigli, Mariarosaria Valente
Restless legs syndrome/Willis-Ekbom disease (RLS/WED) is a sleep-related sensory-motor disorder associated with poor sleep quality and impaired daily functioning. In patients affected by chronic RL...
-
Predictive modelling in pharmacokinetics: from in-silico simulations to personalized medicine Expert Opin. Drug Metab. Toxicol. (IF 4.3) Pub Date : 2024-03-13 Ajita Paliwal, Smita Jain, Sachin Kumar, Pranay Wal, Madhusmruti Khandai, Prasanna Shama Khandige, Vandana Sadananda, Khalid Anwer, Monica Gulati, Tapan Behl, Shriyansh Srivastava
Pharmacokinetic parameters assessment is a critical aspect of drug discovery and development, yet challenges persist due to limited training data. Despite advancements in machine learning and in-si...
-
Beyond the hype and toward application: liver complex in vitro models in preclinical drug safety Expert Opin. Drug Metab. Toxicol. (IF 4.3) Pub Date : 2024-03-13 Sushma Jadalannagari, Lorna Ewart
Drug induced Liver-Injury (DILI) is a leading cause of drug attrition and complex in vitro models (CIVMs), including three dimensional (3D) spheroids, 3D bio printed tissues and flow-based systems,...
-
Cannabidiol: metabolism and clinical efficacy in epileptic patients Expert Opin. Drug Metab. Toxicol. (IF 4.3) Pub Date : 2024-03-11 Giovanni Battista Dell’isola, Alberto Verrotti, Miriam Sciaccaluga, Gianluca Dini, Pietro Ferrara, Lucilla Parnetti, Cinzia Costa
The landscape of epilepsy treatment has undergone a significant transformation with the emergence of cannabidiol as a potential therapeutic agent. Epidiolex, a pharmaceutical formulation of highly ...
-
Drug interactions of carbonic anhydrase inhibitors and activators Expert Opin. Drug Metab. Toxicol. (IF 4.3) Pub Date : 2024-03-07 Claudiu T. Supuran
. Carbonic anhydrases (CAs, EC 4.2.1.1) have been established drug targets for decades, with their inhibitors and activators possessing relevant pharmacological activity and applications in various...
-
The impact of pregnancy and associated hormones on the pharmacokinetics of Δ9-tetrahydrocannabinol Expert Opin. Drug Metab. Toxicol. (IF 4.3) Pub Date : 2024-03-04 Aurora K. Authement, Nina Isoherranen
(-)-Δ9-tetrahydrocannabinol (THC) is the main psychoactive component of cannabis. Cannabis is the most widely used drug of abuse by pregnant individuals, but its maternal-fetal safety is still uncl...
-
How can we optimize the use of methotrexate to treat pediatric patients with inflammatory skin diseases? Expert Opin. Drug Metab. Toxicol. (IF 4.3) Pub Date : 2024-03-01 Kajetan Kiełbowski, Estera Bakinowska, Andrzej Pawlik
Methotrexate (MTX) is a folic acid antagonist used in clinical practice in oncology and rheumatology, as well as in the treatment of inflammatory skin conditions in children. The low-doses of MTX a...
-
What is the impact of metabolic dysfunction associated steatotic liver disease on drug transport and metabolism? Expert Opin. Drug Metab. Toxicol. (IF 4.3) Pub Date : 2024-02-27 Christoph G. Dietrich, Andreas Geier
Published in Expert Opinion on Drug Metabolism & Toxicology (Just accepted, 2024)
-
Comparison of pharmacokinetic properties of alteplase and tenecteplase. The future of thrombolysis in acute ischemic stroke Expert Opin. Drug Metab. Toxicol. (IF 4.3) Pub Date : 2024-02-29 Alessandro Marè, Simone Lorenzut, Francesco Janes, Carolina Gentile, Roberto Marinig, Yan Tereshko, Gian Luigi Gigli, Mariarosaria Valente, Giovanni Merlino
The drug most frequently used for thrombolysis in cases of acute ischemic stroke (AIS) is alteplase. However, there is moderate-to-high-quality evidence that tenecteplase has similar or higher effi...
-
Exploring the level of agreement among different drug-drug interaction checkers: a comparative study on direct oral anticoagulants Expert Opin. Drug Metab. Toxicol. (IF 4.3) Pub Date : 2024-02-22 Massimo Carollo, Salvatore Crisafulli, Francesco Ciccimarra, Giuseppe Andò, Igor Diemberger, Gianluca Trifirò
Direct oral anticoagulants (DOACs) may be involved in drug-drug interactions (DDIs) potentially increasing the risk of adverse drug reactions. This study aimed to evaluate the level of agreement am...
-
Hepatotoxicity of newer antiseizure medications in children: an overview and disproportionality analysis of VigiBase Expert Opin. Drug Metab. Toxicol. (IF 4.3) Pub Date : 2024-02-21 Sanja Petrović, Milena Kovačević, Sandra Vezmar Kovačević, Branislava Miljković
We aimed to characterize newer antiseizure medications (ASMs)-induced hepatotoxicity in children and identify signals of disproportionate reporting of hepatotoxicity-related adverse drug events (AD...
-
Potential benefits and possible risks of CGRP-targeted multitherapy in migraine Expert Opin. Drug Metab. Toxicol. (IF 4.3) Pub Date : 2024-02-12 Keiko Ihara, Tsubasa Takizawa, Narumi Watanabe, Jin Nakahara, Paolo Martelletti
Published in Expert Opinion on Drug Metabolism & Toxicology (Vol. 20, No. 1-2, 2024)
-
What is the risk of hepatotoxicity induced by immune-checkpoint inhibitors and how can we avoid it? Expert Opin. Drug Metab. Toxicol. (IF 4.3) Pub Date : 2024-02-05 Elisa Tassinari, Matteo Rosellini, Andrea Marchetti, Veronica Mollica, Francesco Massari
Published in Expert Opinion on Drug Metabolism & Toxicology (Vol. 20, No. 1-2, 2024)
-
In-silico approaches to assessing multiple high-level drug-drug and drug-disease adverse drug effects Expert Opin. Drug Metab. Toxicol. (IF 4.3) Pub Date : 2024-02-01 Xuan Xu, Jim E Riviere, Shahzad Raza, Nuwan Indika Millagaha Gedara, Remya Ampadi Ramachandran, Lisa A Tell, Gerald J. Wyckoff, Majid Jaberi-Douraki
Pharmacovigilance plays a pivotal role in monitoring adverse events (AEs) related to chemical substances in human/animal populations. With increasing spontaneous-reporting systems, researchers turn...
-
Chronic kidney disease and physiologically based pharmacokinetic modeling: a critical review of existing models Expert Opin. Drug Metab. Toxicol. (IF 4.3) Pub Date : 2024-01-31 Ammara Zamir, Faleh Alqahtani, Muhammad Fawad Rasool
Physiologically based pharmacokinetic (PBPK) modeling is a paradigm shift in this era for determining the exposure of drugs in pediatrics, geriatrics, and patients with chronic diseases where clini...
-
Regulation of PXR in drug metabolism: chemical and structural perspectives Expert Opin. Drug Metab. Toxicol. (IF 4.3) Pub Date : 2024-01-28 Rebecca R. Florke Gee, Andrew D. Huber, Taosheng Chen
Pregnane X receptor (PXR) is a master xenobiotic sensor that transcriptionally controls drug metabolism and disposition pathways. PXR activation by pharmaceutical drugs, natural products, environme...
-
Interindividual variability in statin pharmacokinetics and effects of drug transporters Expert Opin. Drug Metab. Toxicol. (IF 4.3) Pub Date : 2024-01-22 Takeshi Hirota, Ichiro Ieiri
Statins are HMG-CoA reductase inhibitors that primarily lower plasma cholesterol levels. It has been suggested that the myotoxic response is a direct result of hydroxymethylglutaryl-CoA reductase i...
-
Inositols in treating polycystic ovary syndrome and non-insulin dependent diabetes mellitus: now and the future Expert Opin. Drug Metab. Toxicol. (IF 4.3) Pub Date : 2024-01-22 Antonio Simone Laganà, Samuel H. Myers, Gianpiero Forte, Antoine Naem, Harald Krentel, Leila Allahqoli, Ibrahim Alkatout, Vittorio Unfer
This Expert Opinion covers recent updates in the use of Inositol in polycystic ovary syndrome (PCOS) and type II diabetes and gives support to researchers and clinicians.This article discusses the ...
-
Pharmacokinetics and pharmacodynamics of antibody-drug conjugates for the treatment of patients with breast cancer Expert Opin. Drug Metab. Toxicol. (IF 4.3) Pub Date : 2024-01-12 François Cherifi, Angélique Da Silva, Diogo Martins-Branco, Ahmad Awada, Guilherme Nader-Marta
Currently three antibody-drug-conjugates (ADC) are approved by the European Medicines Agency (EMA) for treatment of breast cancer (BC) patient: trastuzumab-emtansine, trastuzumab-deruxtecan and sac...
-
Toxic metabolites and metabolic soft spots of celastrol based on glutathione metabolic capture and high-resolution mass spectrometry Expert Opin. Drug Metab. Toxicol. (IF 4.3) Pub Date : 2024-01-12 Xiaojuan Jiang, Caixia Yuan, Rong Ding, Di Lu, Xiaoyu Peng, Zhihao Dong, Chunyan Zhu, Yihua Lin, Caisheng Wu, Qiang Xie
Celastrol is known as one of the most medicinally valuable compounds. However, the pharmaceutical application of celastrol is significantly limited due to high toxicity, while there are few reports...
-
A pharmacokinetic evaluation of tenapanor for the treatment of irritable bowel syndrome with constipation: an update of the literature Expert Opin. Drug Metab. Toxicol. (IF 4.3) Pub Date : 2024-01-12 Diego Currò, Gianluca Ianiro, Antonio Gasbarrini
Tenapanor is the latest addition to the second-line pharmacotherapeutic options for the treatment of irritable bowel syndrome with constipation. It is a first-in-class inhibitor of type 3 sodium/hy...
-
Evaluation of bioequivalence and safety analysis of capecitabine tablets and Xeloda® under postprandial dosing conditions in Chinese patients with solid tumor Expert Opin. Drug Metab. Toxicol. (IF 4.3) Pub Date : 2024-01-12 Hongtao Li, Rongfang Shan, Jiaxiang Ding, Jialin Zhang, Bingyan Liu, Qin Ge, Dongmei Cheng, Lufeng Li, Chaoyang Zhang, He Su, Xiaoyue Li, Huiru Li, Jingjing Ye, Hui Li, Fengxian Li, Huan Zhou, Qiang Huo, Yue Su
To compare the pharmacokinetic and safety of the test group capecitabine tablets (0.5 g) and the reference group capecitabine tablets (0.5 g).This study was registered at www.chinadrugtrials.org.cn...
-
Pharmacokinetic evaluation of sofosbuvir/velpatasvir for the treatment of Chronic Hepatitis C in pediatrics aged 3 and older Expert Opin. Drug Metab. Toxicol. (IF 4.3) Pub Date : 2024-01-12 Jessica Tuan, Adaora Okoli, Onyema Ogbuagu
The World Health Organization proposed targets to eliminate hepatitis C virus (HCV) by 2030, aiming to treat ≥80% of people with HCV, decreasing new chronic infections by 90% and liver-related mort...
-
CYP3A inhibitor itraconazole affect pharmacokinetic behavior of famitinib and its active metabolite: results of a single-center, single-arm, open-label and fixed sequence study Expert Opin. Drug Metab. Toxicol. (IF 4.3) Pub Date : 2024-01-12 Yunzhe Huang, Yuanwei Jia, Xinyan Chen, Changmao Wang, Yaqin Wang, Minhui Wang, Ping Wu, Jie Shen
Famitinib, the novel oral multitargeting tyrosine kinase inhibitor, was developed for treatment of patients with advanced solid cancer. This investigation assessed the pharmacokinetic (PK) effects ...
-
Drug-drug interactions between COVID-19 therapeutics and psychotropic medications Expert Opin. Drug Metab. Toxicol. (IF 4.3) Pub Date : 2024-01-12 Alessandro Cuomo, Giovanni Barillà, Gianluca Serafini, Andrea Aguglia, Andrea Amerio, Matteo Cattolico, Pietro Carmellini, Alessandro Spiti, Andrea Fagiolini
The coronavirus (COVID-19) pandemic has led to as well as exacerbated mental health disorders, leading to increased use of psychotropic medications. Co-administration of COVID-19 and psychotropic m...
-
A systematic review on the clinical pharmacokinetics of vildagliptin in healthy and disease populations Expert Opin. Drug Metab. Toxicol. (IF 4.3) Pub Date : 2024-01-12 Mahnoor Pasha, Ammara Zamir, Waseem Ashraf, Imran Imran, Hamid Saeed, Anees Ur Rehman, Majid Aziz, Faleh Alqahtani, Muhammad Fawad Rasool
Vildagliptin, a dipeptidyl peptidase-4 inhibitor, is indicated to cure type 2 diabetes mellitus (T2DM). This systematic literature search aims to assess the current knowledge about the clinical pha...
-
Review of human risk factors for idiosyncratic drug-induced liver injury: latest advances and future goals Expert Opin. Drug Metab. Toxicol. (IF 4.3) Pub Date : 2024-01-12 Helgi Kristinn Björnsson, Einar Stefan Björnsson
Idiosyncratic drug-induced liver injury (DILI) is a common cause of acute liver injury and can lead to death from acute liver failure or require liver transplantation. Although the total burden of ...
-
What is the impact of type 2 diabetes mellitus on CYP450 metabolic activities? Expert Opin. Drug Metab. Toxicol. (IF 4.3) Pub Date : 2024-01-12 Brian Tomlinson, Yan-Hong Li
Published in Expert Opinion on Drug Metabolism & Toxicology (Vol. 19, No. 12, 2023)
-
Overview of the pharmacokinetics and pharmacodynamics of URAT1 inhibitors for the treatment of hyperuricemia and gout Expert Opin. Drug Metab. Toxicol. (IF 4.3) Pub Date : 2024-01-12 Zihan Hou, Aijinxiu Ma, Jiale Mao, Danni Song, Xu Zhao
Hyperuricemia is a common metabolic disease, which is a risk factor for gouty arthritis and ureteral stones and may also lead to cardiovascular and chronic kidney disease (CDK). Therefore, hyperuri...
-
Pharmacokinetics and pharmacodynamics of direct oral anticoagulants Expert Opin. Drug Metab. Toxicol. (IF 4.3) Pub Date : 2024-01-12 B. Hindley, G.Y.H. Lip, A.P. McCloskey, P.E. Penson
Direct oral anticoagulants (DOACs) have overtaken vitamin K antagonists to become the most widely used method of anticoagulation for most indications. Their stable and predictable pharmacokinetics ...
-
Predicting the pharmacokinetics and pharmacodynamics of antisense oligonucleotides: an overview of various approaches and opportunities for PBPK/PD modelling Expert Opin. Drug Metab. Toxicol. (IF 4.3) Pub Date : 2024-01-12 Xiang Gao, John K. Diep, Daniel A. Norris, Rosie Z. Yu, Richard S. Geary
Advances in research and development (R&D) have enabled many approvals of antisense oligonucleotides (ASOs). Its administration expanded from systemic to local for treating various diseases, where ...
-
Combined oral contraceptive with estetrol plus drospirenone: from pharmacokinetics to clinical applications Expert Opin. Drug Metab. Toxicol. (IF 4.3) Pub Date : 2024-01-12 Christian Battipaglia, Lia Feliciello, Alessandro D. Genazzani, Fabio Facchinetti, Giovanni Grandi
Drospirenone/estetrol (DRSP/E4) is a combined oral contraceptive (COC) recently approved in several countries. It is composed of 15 mg of E4, a natural estrogen produced by human fetal liver throug...
-
Drug-drug interactions between COVID-19 drug therapies and antidepressants Expert Opin. Drug Metab. Toxicol. (IF 4.3) Pub Date : 2024-01-12 Efstathia Davoutis, Chrysa Panou, Nikolina Stachika, Christina Dalla, Nikolaos Kokras
Antidepressants are widely used for the pharmacological treatment of anxiety and mood disorders. Since the eruption of the SARS-COV-2 pandemic and the later development of targeted treatments again...
-
Metabolic and toxicological considerations regarding CGRP mAbs and CGRP antagonists to treat migraine in COVID-19 patients: a narrative review Expert Opin. Drug Metab. Toxicol. (IF 4.3) Pub Date : 2024-01-12 Tsubasa Takizawa, Keiko Ihara, Shunsuke Uno, Seiya Ohtani, Narumi Watanabe, Noboru Imai, Jin Nakahara, Satoko Hori, David Garcia-Azorin, Paolo Martelletti
Migraine pharmacological therapies targeting calcitonin gene-related peptide (CGRP), including monoclonal antibodies and gepants, have shown clinical effect and optimal tolerability. Interactions b...
-
Where developmental toxicity meets explainable artificial intelligence: state-of-the-art and perspectives Expert Opin. Drug Metab. Toxicol. (IF 4.3) Pub Date : 2023-12-23 Maria Vittoria Togo, Fabrizio Mastrolorito, Angelica Orfino, Elisabetta Anna Graps, Anna Rita Tondo, Cosimo Damiano Altomare, Fulvio Ciriaco, Daniela Trisciuzzi, Orazio Nicolotti, Nicola Amoroso
The application of Artificial Intelligence (AI) to predictive toxicology is rapidly increasing, particularly aiming to develop non-testing methods that effectively address ethical concerns and redu...
-
Overcoming barriers to machine learning applications in toxicity prediction Expert Opin. Drug Metab. Toxicol. (IF 4.3) Pub Date : 2023-12-13 Abdallah Abou Hajal, Ahmad Z. Al Meslamani
Published in Expert Opinion on Drug Metabolism & Toxicology (Ahead of Print, 2023)
-
In-depth mechanistic analysis including high-throughput RNA sequencing in the prediction of functional and structural cardiotoxicants using hiPSC cardiomyocytes Expert Opin. Drug Metab. Toxicol. (IF 4.3) Pub Date : 2023-11-23 Alicia Rosell-Hidalgo, Christopher Bruhn, Emma Shardlow, Ryan Barton, Stephanie Ryder, Timur Samatov, Alexandra Hackmann, Gerald Ryan Aquino, Micael Fernandes Dos Reis, Vladimir Galatenko, Ruediger Fritsch, Cord Dohrmann, Paul A Walker
Cardiotoxicity remains one of the most reported adverse drug reactions that lead to drug attrition during pre-clinical and clinical drug development. Drug-induced cardiotoxicity may develop as a fu...
-
Biosimilars in the treatment of rheumatoid arthritis: a pharmacokinetic overview Expert Opin. Drug Metab. Toxicol. (IF 4.3) Pub Date : 2023-11-17 Yeo-Jin Song, Seoung Wan Nam, Chang Hee Suh, Jung Yoon Choe, Dae Hyun Yoo
As of May 2023, 19 and 18 biosimilars have been approved for the treatment of rheumatoid arthritis (RA) by the European Medicines Agency (EMA) and United States Food and Drug Administration (US FDA...
-
Drug–drug interactions between COVID-19 therapeutics and antiretroviral treatment: the evidence to date Expert Opin. Drug Metab. Toxicol. (IF 4.3) Pub Date : 2023-11-17 Camden Ellis, Keita Inaba, Christine Van de Vuurst, Atheel Ghrayeb, Theodore James Cory
With new effective treatments for SARS-CoV-2, patient outcomes have greatly improved. However, new medications bring a risk of drug interactions with other medications. People living with HIV (PLWH...
-
Drug-drug interactions between antiseizure medications and antipsychotic medications: a narrative review and expert opinion Expert Opin. Drug Metab. Toxicol. (IF 4.3) Pub Date : 2023-11-17 Frank M. C. Besag, Dave Berry, Michael J. Vasey, Philip N. Patsalos
Antiseizure medications (ASMs) and antipsychotic drugs are frequently coadministered with the potential for drug-drug interactions. Interactions may either be pharmacokinetic or pharmacodynamic, re...
-
A repeat-dose toxicity study of human umbilical cord mesenchymal stem cells in NOG mice by intravenous injection Expert Opin. Drug Metab. Toxicol. (IF 4.3) Pub Date : 2023-11-17 Jinjin Shao, Lijuan Xia, Zhichao Ye, Qian Yang, Chengda Zhang, Yuhua Shi, Lili Zhang, Liqiang Gu, Cong Xu, Ying Chen, Yunxiang Chen, Xin Pan, Feifei Wu, Ruolang Pan, Jinfeng Liang, Lijiang Zhang
Stem cell-based therapies have demonstrated great potential in several clinical trials. However, safety data on stem cell application remain inadequate. This study evaluated the toxicity of human u...
-
Tyrosine kinase inhibitors: the role of pharmacokinetics and pharmacogenetics Expert Opin. Drug Metab. Toxicol. (IF 4.3) Pub Date : 2023-11-17 Allegra Sarah, Emma Dondi, Silvia De Francia
Published in Expert Opinion on Drug Metabolism & Toxicology (Vol. 19, No. 11, 2023)
-
Common gastrointestinal drug-drug interactions in geriatrics and the importance of careful planning Expert Opin. Drug Metab. Toxicol. (IF 4.3) Pub Date : 2023-11-17 Shilan Mozaffari, Taraneh Mousavi, Shekoufeh Nikfar, Mohammad Abdollahi
Polypharmacy, which uses multiple medications to treat chronic illnesses, is common among elderly patients. However, it can lead to drug interactions, especially with gastrointestinal (GI) medicine...
-
The use of glucarpidase as a rescue therapy for high dose methotrexate toxicity – a review of pharmacological and clinical data Expert Opin. Drug Metab. Toxicol. (IF 4.3) Pub Date : 2023-11-17 Kajetan Kielbowski, Jakub Rosik, Estera Bakinowska, Ewa Gromowska, Łukasz Ustianowski, Bartosz Szostak, Andrzej Pawlik
This review aims to summarize recent data on the pharmacodynamic, pharmacokinetic, and safety of glucarpidase. This is an enzymatic agent that catalyzes the conversion of methotrexate (MTX) into in...
-
Evaluating the pharmacokinetic and pharmacodynamic impact of different modes of ticagrelor administration Expert Opin. Drug Metab. Toxicol. (IF 4.3) Pub Date : 2023-11-17 Marco Spagnolo, Dominick J. Angiolillo, Davide Capodanno
Alternative administration modes for oral P2Y12 inhibitors, particularly ticagrelor, have emerged as a potential alternative to overcome the limitations associated with the delayed onset of action ...
-
Pharmacokinetic considerations for angiogenesis inhibitors used to treat hepatocellular carcinoma: an overview Expert Opin. Drug Metab. Toxicol. (IF 4.3) Pub Date : 2023-11-17 Raffaele Borriello, Lucia Cerrito, Antonio Gasbarrini, Francesca Romana Ponziani
Hepatocellular carcinoma (HCC) is the fifth malignancy in terms of frequency and the fourth malignancy in terms of cancer-related death worldwide. Systemic therapy of advanced HCC has probably gone...
-
Improving on in-silico prediction of oral drug bioavailability Expert Opin. Drug Metab. Toxicol. (IF 4.3) Pub Date : 2023-10-27 Saeed Alqahtani
Although significant development has been made in high-throughput screening of oral drug absorption and oral bioavailability, in silico prediction continues to play an important role in prediction ...
-
Clinical pharmacology of selatogrel for self-administration by patients with suspected acute myocardial infarction Expert Opin. Drug Metab. Toxicol. (IF 4.3) Pub Date : 2023-10-27 Martine Gehin, Robert F. Storey, Corine Bernaud, Jasper Dingemanse
P2Y12 receptor antagonists (P2Y12 inhibitors) are well established for the treatment of coronary artery disease. The P2Y12 inhibitors currently commercially available present either pharmacokinetic...
-
The safety and toxicity profile of SPL84, an inhaled antisense oligonucleotide for treatment of cystic fibrosis patients with the 3849 +10kb C->T mutation, supports a Phase 1/2 clinical study Expert Opin. Drug Metab. Toxicol. (IF 4.3) Pub Date : 2023-10-27 Lital Friedman, Ofra-Barchad Avitzur, Efrat Ozeri Galai, Nicolay Ferrari, Asa Choen, Sara Dahan, Tamar Mordechai, Gili Hart
SPL84 is an inhaled antisense oligonucleotide (ASO) in development for the treatment of cystic fibrosis (CF) patients carrying the 3849 + 10kb C->T (3849) mutation. To support the initiation of the...
-
Enhancing drug-drug Interaction Prediction by Integrating Physiologically-Based Pharmacokinetic Model with Fraction Metabolized by CYP3A4 Expert Opin. Drug Metab. Toxicol. (IF 4.3) Pub Date : 2023-10-27 Pin Jiang, Tao Chen, Lin-Feng Chu, Ren-Peng Xu, Jin-Ting Gao, Li Wang, Qiang Liu, Lily Tang, Hong Wan, Ming Li, Hong-Can Ren
Enhancing the precision of drug–drug interaction (DDI) prediction is essential for improving drug safety and efficacy. The aim is to identify the most effective fraction metabolized by CY3A4 (fm) f...
-
What is the most effective and safest Non-steroidal anti-inflammatory drug for treating osteoarthritis in patients with comorbidities? Expert Opin. Drug Metab. Toxicol. (IF 4.3) Pub Date : 2023-10-27 Quentin E Geczy, Aricia J Thirumaran, Peter R Carroll, Andrew J McLachlan, David J Hunter
Understanding what the most effective and safe non-steroidal anti-inflammatory drug (NSAID) is for managing osteoarthritis (OA) is complicated. OA is prevalent worldwide and people living with OA c...
-
Pharmacology of viable mechanism agnostic respiratory stimulants for the reversal of drug-induced respiratory depression in humans Expert Opin. Drug Metab. Toxicol. (IF 4.3) Pub Date : 2023-10-27 Maarten van Lemmen, Rutger van der Schrier, Albert Dahan, Monique van Velzen, Elise Sarton, Marieke Niesters
Drug-induced respiratory depression is potentially fatal and can be caused by various drugs such as synthetic opioids and tranquilizers. The only class of respiratory depressants that has a specifi...
-
Correction Expert Opin. Drug Metab. Toxicol. (IF 4.3) Pub Date : 2023-10-12
Published in Expert Opinion on Drug Metabolism & Toxicology (Vol. 19, No. 9, 2023)
-
Phase 1 study to evaluate the effects of rifampin or itraconazole on the pharmacokinetics of limertinib (ASK120067), a novel mutant-selective inhibitor of the epidermal growth factor receptor in healthy Chinese subjects. Expert Opin. Drug Metab. Toxicol. (IF 4.3) Pub Date : 2023-10-12 Bei Cao,Lei Huang,Ming Liu,Hui Lin,Tingting Ma,Yu Zhao,Yan Geng,Yuanxun Yang,Haifang Guo,Juan Li
BACKGROUND Limertinib is a novel mutant-selective and irreversible inhibitor of the epidermal growth factor receptor under development. A phase 1 open, two-period, single-sequence, self-controlled, two-part study was initiated to characterize the effects of a strong CYP3A4 inducer (rifampin) or inhibitor (itraconazole) on the pharmacokinetics of limertinib. RESEARCH DESIGN AND METHODS Twenty-four healthy
-
Effects of natural products on cisplatin ototoxicity and chemotherapeutic efficacy Expert Opin. Drug Metab. Toxicol. (IF 4.3) Pub Date : 2023-09-20 Leonard P. Rybak, Ian Alberts, Shree Patel, Raheem Al Aameri, Vickram Ramkumar
Cisplatin is a very effective chemotherapeutic agent against a variety of solid tumors. Unfortunately, cisplatin causes permanent sensorineural hearing loss in at least two-thirds of patients treat...
-
The pharmacokinetic evaluation of omadacycline (oral only dosing regimen) for the treatment of community-acquired bacterial pneumonia (CABP) Expert Opin. Drug Metab. Toxicol. (IF 4.3) Pub Date : 2023-09-20 Catia Cilloniz, Antoni Torres
Omadacycline is a new analog of the tetracycline class active against atypical bacteria, as well as against staphylococci, including methicillin-resistant strains, and Streptococcus pneumoniae.This...
-
Advances in the understanding of acetaminophen toxicity mechanisms: a clinical toxicology perspective Expert Opin. Drug Metab. Toxicol. (IF 4.3) Pub Date : 2023-09-15 Angela L. Chiew, Geoffrey K. Isbister
Acetaminophen (paracetamol) is a commonly used analgesic and antipyretic agent, which is safe in therapeutic doses. Acetaminophen poisoning due to self-harm or repeated supratherapeutic ingestion i...
-
Metabolic and toxicological considerations for phosphoinositide 3-kinase delta inhibitors in the treatment of chronic lymphocytic leukemia Expert Opin. Drug Metab. Toxicol. (IF 4.3) Pub Date : 2023-09-15 Magdalena Witkowska, Agata Majchrzak, Paweł Robak, Anna Wolska-Washer, Tadeusz Robak
Phosphoinositide 3-kinase delta (PI3Kδ) inhibitors are a class of novel agents that are mainly used to treat B-cell malignancies. They function by inhibiting one or more enzymes which are part of t...
-
Pharmacokinetic and pharmacodynamic considerations for optimizing antimicrobial therapy used to treat bone and joint infections: an evidence-based algorithmic approach Expert Opin. Drug Metab. Toxicol. (IF 4.3) Pub Date : 2023-09-14 Milo Gatti, Sara Tedeschi, Eleonora Zamparini, Federico Pea, Pierluigi Viale
Bone and joint infections (BJIs) are a major health concern causing remarkable morbidity and mortality. However, which antimicrobial treatment could be the best according to specific clinical scena...